Abstract
Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Current Pharmaceutical Design
Title:Congenital Hypothyroidism: Facts, Facets & Therapy
Volume: 23 Issue: 16
Author(s): Yedukondalu Kollati, Ranga Rao Ambati, Prakash Narayana Reddy, N. Satya Sampath Kumar, Rajesh K. Patel*Vijaya R. Dirisala*
Affiliation:
- Sandor Animal Biogenics Private Limited, Sandor Life Sciences, Telangana-500043,India
- Department of Biotechnology, Vignan’s Foundation for Science, Technology and Research University (VFSTRU), Guntur-5222, Andhra Pradesh,India
Keywords: Congenital hypothyroidism, hormone therapy, levothyroxine, thyroid gland, transcription factors, Thyroid hormone (T3).
Abstract: Background: Thyroid hormone (T3) is essential for normal development of children enabling brain development and somatic growth. However, certain individuals are genetically predisposed with insufficient or no thyroid hormones. Such a condition is termed congenital hypothyroidism (CH).
Objective: In the present review, a brief back ground about congenital hypothyroidism, factors associated with CH leading to thyroid dysgenesis and thyroid dyshormonogenesis is elaborated. Additionally, the guidelines for available treatment options, management and follow-up required for patients diagnosed with CH are discussed. Treatment options in terms of treatment initiation and dosage of hormone replacement are discussed. Conclusion: Though CH is considered as the most common neonatal metabolic disorder, it is also easily treatable compared to other metabolic or hereditary diseases. The outcome of CH treatment depends on the compliance of parents early in life and by patients themselves during later part of life.Export Options
About this article
Cite this article as:
Kollati Yedukondalu, Ambati Rao Ranga, Reddy Narayana Prakash, Kumar Satya Sampath N., Patel K. Rajesh*, Dirisala R. Vijaya*, Congenital Hypothyroidism: Facts, Facets & Therapy, Current Pharmaceutical Design 2017; 23 (16) . https://dx.doi.org/10.2174/1381612823666170206124255
DOI https://dx.doi.org/10.2174/1381612823666170206124255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Role of Myocardial Collagen Network in Hypertensive Heart Disease
Current Hypertension Reviews Endothelin-1 Signaling in Vascular Physiology and Pathophysiology
Current Vascular Pharmacology Dietary Fatty Acids in Metabolic Syndrome, Diabetes and Cardiovascular Diseases
Current Diabetes Reviews Combined Anticancer Therapies: An Overview of the Latest Applications
Anti-Cancer Agents in Medicinal Chemistry Current Status of Therapeutic Angiogenesis with Protein, Gene and Cell Therapy
Current Drug Therapy Transient Receptor Potential Channels - Emerging Novel Drug Targets for the Treatment of Pain
Current Medicinal Chemistry Gender Differences in Ischemic Heart Disease
Recent Patents on Cardiovascular Drug Discovery Angiogenesis Inhibitors: Implications for Combination with Conventional Therapies
Current Pharmaceutical Design Do Adult Stem Cells Ameliorate the Damaged Myocardium? Human Cord Blood as a Potential Source of Stem Cells
Current Vascular Pharmacology A Review of Chinese Herbal Medicine for the Treatment of Chronic Heart Failure
Current Pharmaceutical Design Natural Products as Anti-Cancerous Therapeutic Molecules Targeted towards Topoisomerases
Current Protein & Peptide Science Recent Advancement in the Treatment of Cardiovascular Diseases: Conventional Therapy to Nanotechnology
Current Pharmaceutical Design Cardiovascular Effects of Glucagon-Like Peptide 1
Mini-Reviews in Medicinal Chemistry Novel Insights into Complex Cardiovascular Pathologies using 4D Flow Analysis by Cardiovascular Magnetic Resonance Imaging
Current Pharmaceutical Design The Impact of Traditional Chinese Medicine on Mitophagy in Disease Models
Current Pharmaceutical Design How does Chronic Atrial Fibrillation Influence Mortality in the Modern Treatment Era?
Current Cardiology Reviews Dietary Antioxidants: Immunity and Host Defense
Current Topics in Medicinal Chemistry Cytochrome P450 and the Biological Clock in Mammals
Current Drug Metabolism Fetuin-A: A Multifunctional Protein
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Targeting Indoleamine 2,3-dioxygenase (IDO) to Counteract Tumour- Induced ImmuneDysfunction: From Biochemistry to Clinical Development
Endocrine, Metabolic & Immune Disorders - Drug Targets